Resof total 400mg/100mg Tablet

Resof total 400mg/100mg Tablet   is a combination of two antiviral medicines such as Sofosbuvir and Velpatasvir. It is used in the treatment of Chronic hepatitis C virus (HCV) infection.

It works by blocking the replication of the virus to reduce its levels in the body. By suppressing viral replication, it helps to slow down the progression of liver damage and clear up the infection. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.

• Chronic hepatitis C virus (HCV) infection

Resof total 400mg/100mg Tablet is a strong anti-HIV medicine that may show certain adverse while manageable impact on the body during the treatment. As these effects resolve on their own without any special medical attention. However, if you ever experience serious or unusual side effects contact your healthcare professional immediately.

Some common side effects include:

• Headache
• Diarrhea
• Insomnia (difficulty sleeping)
• Anemia (low number of red blood cells)
• Nausea
• Fatigue

• Take Resof total 400mg/100mg Tablet in exact dose as prescribed by the doctor. The typical dose of this capsule varies with age and overall health factor of the patient. It can be taken with or without food but at a fixed time each day to get better results.
• It should be swallowed as a whole with water without crushing, chewing, or opening the capsule. Don't miss a dose or overdose the medicine.

• Resof total 400mg/100mg Tablet   is a combination of two antiviral medicines such as Sofosbuvir and Velpatasvir. It works by blocking the replication of the virus to reduce its levels in the body.
• By suppressing viral replication, it helps to slow down the progression of liver damage and clear up the infection. It should be taken in dose and duration as advice by the doctor.

• Wyles, D., Bräu, N., Kottilil, S., Daar, E. S., Ruane, P., Workowski, K., ... & ASTRAL-5 Investigators. (2017). Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study. Clinical Infectious Diseases, 65(1), 6-12.
• Pianko, S., Flamm, S. L., Shiffman, M. L., Kumar, S., Strasser, S. I., Dore, G. J., ... & Roberts, S. K. (2015). Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Annals of internal medicine, 163(11), 809-817.
• Foster, G. R., Afdhal, N., Roberts, S. K., Bräu, N., Gane, E. J., Pianko, S., ... & Sulkowski, M. (2015). Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. New England Journal of Medicine, 373(27), 2608-2617.
• Jackson, W. E., & Everson, G. T. (2017). Sofosbuvir and velpatasvir for the treatment of hepatitis C. Expert review of gastroenterology & hepatology, 11(6), 501-505.
• Feld, J. J., Jacobson, I. M., Hézode, C., Asselah, T., Ruane, P. J., Gruener, N., ... &Zeuzem, S. (2015). Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine, 373(27), 2599-2607.